Suggested remit - To appraise the clinical and cost effectiveness of ozanimod within its marketing authorisation for treating relapsing multiple sclerosis.
Status Proposed
Process STA 2018
ID number 1294

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
30 January 2018 - 27 February 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance